The SURMOUNT trials showed tirzepatide at 15 mg producing over 22% body weight loss on average, compared to roughly 15% for semaglutide 2.4 mg in the STEP trials
He or she can run tests and there is also genetics counseling available to determine your risk
The approval was based on the OASIS clinical trial programme and the SELECT cardiovascular outcomes trial, with the OASIS 4 study showing a mean weight loss of 16.6% at 64 weeks in adults with obesity or overweight, among participants who adhered to treatment
The increasing use of GLP-1s, along with the recently issued coverage guidance by the CMS, will present several important factors for plans to consider in the future
Given the challenges obesity poses in this fieldincluding increased perioperative risk, altered musculoskeletal biomechanics, and poorer long-term outcomesGLP-1 agonists may play a valuable role in optimizing orthopedic surgical care
Simple, repeatable habits like more protein, more fiber, fermented foods, and colorful plants can work with your bodys natural systems over time
